Join the 'Leukemia' group to help and get support from people like you.

Leukemia Blog

Related terms: Cancer, Leukemia

Experimental Drug May Boost Leukemia Survival, Without Chemo

Posted 12 Mar 2014 by Drugs.com

WEDNESDAY, March 12, 2014 – An experimental drug may extend the lives of people with certain hard-to-treat forms of leukemia and lymphoma – without the need for traditional chemotherapy, according to two studies released Wednesday. The drug, called idelalisib, targets a specific enzyme on white blood cells known as B cells. Researchers found that for people with certain forms of recurrent blood cancers, the drug substantially extended the time that patients lived with no tumor progression. One of the trials, of patients with chronic lymphocytic leukemia (CLL), was stopped early because the benefits of idelalisib over standard treatment became so clear. The drug is now up for expedited review by the U.S. Food and Drug Administration (FDA), for possible approval. A cancer researcher not involved in either trial called the CLL results "fantastic." If idelalisib is approved, "I think ... Read more

Related support groups: Leukemia, Lymphoma, Chronic Lymphocytic Leukemia (CLL)

Gene Variations Leave Infants at Risk of Leukemia, Study Suggests

Posted 19 Feb 2014 by Drugs.com

WEDNESDAY, Feb. 19, 2014 – Infants who develop leukemia before they're 1 year old have inherited gene mutations that put them at high risk for the disease, a small study suggests. The findings might one day lead to new treatments for leukemia in infants, the study authors said. The causes of cancer in babies have been difficult to pinpoint. For one thing, they haven't been alive long enough to amass the number of gene mutations that can trigger cancer. "Parents always ask why their child has developed leukemia, and unfortunately we have had few answers," study senior author Dr. Todd Druley, a pediatric oncologist at Washington University School of Medicine in St. Louis, said in a university news release. "Our study suggests that babies with leukemia inherit a strong genetic predisposition to the disease," he explained. Druley and his colleagues analyzed the genes of 23 infants with ... Read more

Related support groups: Leukemia

FDA Approves Imbruvica to Treat Chronic Lymphocytic Leukemia

Posted 12 Feb 2014 by Drugs.com

February 12, 2014 – The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) for chronic lymphocytic leukemia (CLL) patients who have received at least one previous therapy. CLL is a rare blood and bone marrow disease that usually gets worse slowly over time, causing a gradual increase in white blood cells called B lymphocytes, or B cells. The National Cancer Institute estimates that 15,680 Americans were diagnosed and 4,580 died from the disease in 2013. Imbruvica works by blocking the enzyme that allows cancer cells to grow and divide. In November 2013, the FDA granted Imbruvica accelerated approval to treat patients with mantle cell lymphoma, a rare and aggressive type of blood cancer, if those patients received at least one prior therapy. “Today’s approval provides an important new treatment option for CLL patients whose cancer has pro ... Read more

Related support groups: Leukemia, Chronic Lymphocytic Leukemia (CLL), Imbruvica, Ibrutinib

New Drug Combo Might Help Older, Sicker Patients With Leukemia

Posted 9 Jan 2014 by Drugs.com

THURSDAY, Jan. 9, 2014 – A new combination of drugs might prolong life in certain older leukemia patients, a new study suggests. The research, led by German scientists, included nearly 800 older people (average age 73) who had been diagnosed with chronic lymphocytic leukemia. CLL is a cancer of the blood and bone marrow, the tissue inside bones in which blood cells are created. The study was published online Jan. 8 in the New England Journal of Medicine. Study participants – none of whom had received treatment for their illness before the start of the research – were randomly assigned to one of three groups. One group received an oral medication called chlorambucil (also known by the brand name Leukeran), the standard chemotherapy drug for older patients with CLL. The second group received chlorambucil plus a drug called rituximab (Rituxan). This drug has been used effectively in ... Read more

Related support groups: Leukemia, Rituxan, Rituximab, Leukeran, Chlorambucil, Gazyva, Obinutuzumab

Gene Therapy Shows Promise Against Leukemia, Other Blood Cancers

Posted 9 Dec 2013 by Drugs.com

SUNDAY, Dec. 8, 2013 – Preliminary research shows that gene therapy might one day be a powerful weapon against leukemia and other blood cancers. The experimental treatment coaxed certain blood cells into targeting and destroying cancer cells, according to research presented this weekend at the American Society of Hematology's annual meeting in New Orleans. "It's really exciting," Dr. Janis Abkowitz, blood diseases chief at the University of Washington in Seattle and president of the American Society of Hematology, told the Associated Press. "You can take a cell that belongs to a patient and engineer it to be an attack cell." At this point, more than 120 patients with different types of blood and bone marrow cancers have been given the treatment, according to the wire service, and many have gone into remission and stayed in remission up to three years later. In one study, all five ... Read more

Related support groups: Leukemia

Study: Pollen Allergies May Raise Risk for Blood Cancers in Women

Posted 4 Dec 2013 by Drugs.com

WEDNESDAY, Dec. 4, 2013 – Women with pollen allergies may be at increased risk for blood cancers such as leukemia and lymphoma, a new study suggests. Researchers did not uncover the same link in men. This suggests there is something unique in women that causes chronic allergy-related stimulation of the immune system to increase vulnerability to the development of blood cancers, the study authors said. The study included 66,000 people, aged 50 to 76, who were followed for an average of eight years. During the follow-up period, 681 people developed a blood cancer. These people were more likely to be male, to have two or more first-degree relatives with a history of leukemia or lymphoma, to be less active and to rate their health status as poor. Among women, however, a history of allergies to plants, grass and trees was significantly associated with a higher risk of blood cancers. The ... Read more

Related support groups: Allergies, Leukemia, Lymphoma

Kids' Cancer Treatments May Cause Heart Trouble, Study Says

Posted 17 Nov 2013 by Drugs.com

SUNDAY, Nov. 17, 2013 – Children who survive cancer often have treatment-related changes to their arteries that may put them at risk for heart disease while still in childhood, a new study says. The finding suggests doctors need to monitor these patients earlier, and manage their risk factors for heart diseases while they are still young. "Research has shown childhood cancer survivors face heart and other health problems decades after treatment," study author Donald Dengel, a kinesiology professor at the University of Minnesota in Minneapolis, said in an American Heart Association news release. "But researchers had not, until now, looked at the heart health effects of childhood cancer treatment while survivors are still children." The researchers assessed artery stiffness, thickness and function in more than 300 boys and girls, ages 9 to 18, who had survived at least five years since ... Read more

Related support groups: Cancer, Leukemia

FDA Approves Gazyva for Chronic Lymphocytic Leukemia

Posted 3 Nov 2013 by Drugs.com

November 1, 2013 – The U.S. Food and Drug Administration today approved Gazyva (obinutuzumab) for use in combination with chlorambucil to treat patients with previously untreated chronic lymphocytic leukemia (CLL). CLL is a blood and bone marrow disease that usually gets worse slowly. According to the National Cancer Institute, 15,680 Americans will be diagnosed and 4,580 will die from the disease this year. Gazyva works by helping certain cells in the immune system attack cancer cells. Gazyva is intended to be used with chlorambucil, another drug used to treat patients with CLL. Gazyva is the first drug with breakthrough therapy designation to receive FDA approval. This designation was requested by the sponsor and granted soon after the biologic license application to support marketing approval was submitted to the FDA. The FDA can designate a drug a breakthrough therapy at the ... Read more

Related support groups: Leukemia, Chronic Lymphocytic Leukemia (CLL)

FDA Medwatch Alert: Iclusig (Ponatinib): Drug Safety Communication - Increased Reports Of Serious Blood Clots In Arteries And Veins

Posted 31 Oct 2013 by Drugs.com

UPDATED 10/31/2013. FDA has asked, and Ariad Pharmaceuticals has agreed, to suspend marketing and sales of Iclusig (ponatinib), a leukemia chemotherapy drug, because of the risk of life-threatening blood clots and severe narrowing of blood vessels. FDA will continue to evaluate the drug to further understand its risks and potential patient populations in which the benefits of the drug may outweigh the risks. Patients currently receiving Iclusig should discuss with their health care professionals the risks and benefits of continuing treatment with the drug.   [Posted 10/11/2013] AUDIENCE: ISSUE: FDA is investigating an increasing frequency of reports of serious and life-threatening blood clots and severe narrowing of blood vessels (arteries and veins) of patients taking the leukemia chemotherapy drug Iclusig (ponatinib). Data from clinical trials and postmarket adverse event reports show ... Read more

Related support groups: Leukemia, Iclusig

FDA Medwatch Alert: Iclusig (Ponatinib): Drug Safety Communication - Increased Reports Of Serious Blood Clots In Arteries And Veins

Posted 14 Oct 2013 by Drugs.com

ISSUE: FDA is investigating an increasing frequency of reports of serious and life-threatening blood clots and severe narrowing of blood vessels (arteries and veins) of patients taking the leukemia chemotherapy drug Iclusig (ponatinib). Data from clinical trials and postmarket adverse event reports show that serious adverse events have occurred in patients treated with Iclusig, including heart attacks resulting in death, worsening coronary artery disease, stroke, narrowing of large arteries of the brain, severe narrowing of blood vessels in the extremities, and the need for urgent surgical procedures to restore blood flow. FDA is actively working to further evaluate these adverse events and will notify the public when more information is available.   BACKGROUND: Iclusig is a prescription medicine used to treat adults diagnosed with chronic phase, accelerated phase, or blast phase chron ... Read more

Related support groups: Leukemia, Iclusig, Ponatinib

Gene Discovery May Offer Breakthrough for Rare Leukemia

Posted 10 May 2013 by Drugs.com

THURSDAY, May 9 – In the war against cancer, it looks like matchmaking – between genes and drugs – could be an important tool, according to new research into the genetic underpinnings of two rare forms of leukemia. By matching a patient's genetic mutation responsible for a rare, rapidly progressing form of leukemia with a drug that specifically targets the problem the mutation creates, researchers report that one patient is experiencing fast, marked improvement. The new findings shed light on how many forms of cancer may be tackled in the near future. Scientists are discovering how to differentiate between mutations that are driving the proliferation of cancer cells and those that are merely passengers in the process. "If your car breaks down, you have to open up the hood to see what part has broken," said study author Jeffrey Tyner, an assistant professor at the Knight Cancer ... Read more

Related support groups: Leukemia, Chronic Myelogenous Leukemia (CML)

Soaring Prices Keep Leukemia Drugs From Patients, Experts Say

Posted 25 Apr 2013 by Drugs.com

THURSDAY, April 25 – Pricey cancer medications prevent many Americans with chronic myeloid leukemia (CML) from receiving lifesaving treatment, an international team of experts claims. These drugs can cost more than $100,000 a year for patients with CML, once considered a death sentence but now highly treatable with ongoing treatment, according to a commentary penned by 120 specialists in more than 15 countries and published online April 25 in the journal Blood. "Patients with CML have a much better outlook today than ever before, thanks to advances that have greatly improved survival rates. But these patients now face dire financial struggles as they try to maintain their treatment regimen with the drastically inflating cost of care," corresponding author Dr. Hagop Kantarjian, chairman of the leukemia department at the University of Texas MD Anderson Cancer Center in Houston, said in a ... Read more

Related support groups: Leukemia, Chronic Myelogenous Leukemia (CML), Gleevec, Sprycel, Dasatinib, Imatinib, Bosulif, Bosutinib, Synribo, Omacetaxine

Leukemia Patients Get Treatment Boost From Donors' Immune Cells

Posted 27 Feb 2013 by Drugs.com

WEDNESDAY, Feb. 27 – Researchers say they've found a way to tweak and strengthen immune cells to maximize their leukemia-fighting capability while minimizing their toxic effects on the patient. The chemotherapy that leukemia patients typically receive to kill cancer cells can also destroy the body's ability to produce new blood cells, the U.S. researchers explained. And while bone marrow transplants can restore the body's ability to produce blood cells, that procedure is also a double-edged sword: If the donor is not perfectly matched, the new donor cells can attack the patient, resulting in potentially life-threatening graft-versus-host disease. Given the limitations of these two standard treatments, "researchers have long sought ways to maximize the anti-leukemic response in these [bone marrow] transplants while minimizing the risk to host tissues," explained David Wiest, deputy ... Read more

Related support groups: Leukemia

FDA Approves Gleevec for Children with Acute Lymphoblastic Leukemia

Posted 25 Jan 2013 by Drugs.com

January 25, 2013 – The U.S. Food and Drug Administration today approved a new use of Gleevec (imatinib) to treat children newly diagnosed with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). ALL is the most common type of pediatric cancer, affecting approximately 2,900 children annually, and progresses quickly if untreated. Children with Ph+ ALL have a genetic abnormality that causes proteins called tyrosine kinases to stimulate the bone marrow to make too many immature white blood cells. This leaves less room for healthy white blood cells needed to fight infection. Gleevec, a tyrosine kinase inhibitor, blocks the proteins that promote the development of cancerous cells. It should be used in combination with chemotherapy to treat children with Ph+ ALL. “We are pleased that the number of cancer medications for children are on the rise,” said Richard Pazdur, ... Read more

Related support groups: Leukemia, Gleevec, Acute Lymphoblastic Leukemia, Imatinib

FDA Approves Iclusig to Treat Two Rare Types of Leukemia

Posted 17 Dec 2012 by Drugs.com

December 14, 2012 - The U.S. Food and Drug Administration today approved Iclusig (ponatinib) to treat adults with chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), two rare blood and bone marrow diseases. Iclusig is being approved more than three months ahead of the product’s prescription user fee goal date of March 27, 2013, the date the agency was scheduled to complete review of the drug application. The FDA reviewed the Iclusig drug application under the agency’s priority review program, which provides for an expedited six-month review for drugs that may provide safe and effective therapy when no satisfactory alternative therapy exists, or offer significant improvement compared to marketed products. Iclusig blocks certain proteins that promote the development of cancerous cells. The drug is taken once a day to treat patients ... Read more

Related support groups: Leukemia, Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia

Page 1 2 3 Next

Ask a Question

Further Information

Related Condition Support Groups

Chronic Myelogenous Leukemia (CML), Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia (CLL), Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Nonlymphocytic Leukemia, Hairy Cell Leukemia, Acute Myeloblastic Leukemia, Meningeal Leukemia, Chronic Eosinophilic Leukemia, Blood Disorders

Related Drug Support Groups

prednisone, triamcinolone, dexamethasone, Decadron, Sprycel, Aristocort, Kenalog-40, dasatinib, Deltasone, view more... Sterapred, cytarabine, Cytosar, Liquid Pred, Sterapred DS, Cytosar-U, Fludara, fludarabine, Adrenocot, Kenaject-40, Cort-K, Tramacort-D, Triam-Forte, TAC 3, Triamcot, Tristoject, Triamonide 40, Triam-A, Idamycin, Oforta, Dexamethasone Intensol, Baycadron, Dalalone, Decaject, Prednicot, Ken-Jec 40, Trilone, U-Tri-Lone, Clinacort, Clinalog, Trilog, Dexacorten, Solurex LA, Dexacen-4, Solurex, De-Sone LA, Decadron-LA, Hexadrol, idarubicin, Idamycin PFS, Tarabine PFS, Dexacort-LA, Dexasone, Medidex LA, Dexpak Taperpak, Meticorten, Orasone, Medidex, Primethasone, Dexasone LA, Dexone, Dexone LA, Prednicen-M